MIT mRNA therapeutics spinout Strand has secured series A funding from BeiGene, Redmile Group, Camford Capital, Playground Global and Anri.

Strand Therapeutics, a US-based messenger RNA (mRNA) drug developer spun out of Massachusetts Institute of Technology (MIT), secured $52m in series A funding yesterday. Biopharmaceutical company BeiGene provided the cash along with hedge fund manager Redmile Group and venture capital firms Camford Capital, Playground Global and Anri. Founded in 2017, Strand is working on mRNA…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.